

W. Border et al.

Serial No.: 07/416,656 Filed: October 3, 1989

Page 2


In the claims:

Claims 2 and 5, each line 1, after "1" add --or 19--

Claims 7 and 10, each line 1, after "6" to add --or 20

treating pathologies

Please amend claims 1, 6 and 13 under the provisions of 37 C.F.R. § 1.121(b) by deleting the bracketed material and inserting the underlined material as follows:



A method of inhibiting the accumulation of --6. (twice amended) extracellular matrix in a tissue comprising [suppressing the extracellular matrix producing activity of TGF-B in the tissue by] contacting the tissue with |a/n| effective amount of a TGF-B inhibitory [specific] agent which suppresses the accumulation of a TGF-B induced component of said extracellular matrix in said tissue [to inhibit said accumulation] .--



--13. (twice amended) A method of decreasing the production of a  $\underline{\text{TGF-B}}$  induced proteoglycan by a cell which produces [a]  $\underline{\text{the}}$ proteoglycan, comprising contacting the cell with an agent which decreases [decreasing] the amount of TGF-B or [inhibiting] inhibits the proteoglycan [production stimulating] inducing activity of TGF-B in contact with the cell, and wherein the agent is not a general protein inhibitor [to which the cell exposed] .--